Alpha Tau Medical
DRTS on Nasdaq. Surgical & medical instruments & apparatus. Market value $1.4bn.
This company reports once a year (it is based outside the US), so every figure comes from its annual report for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
Nothing stands out yet.
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-2.57 of spare cash last year. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$14.48 a share, 322% above its 1-year low
Over the past year the price has ranged from $3.43 to $15.79.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating margin | |||||
| Operating margin | n/a | n/a | n/a | n/a | n/a |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.07bn | 0.07bn | 0.07bn | 0.07bn | 0.09bn |
Health checks
- Free cash flow positive0 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)Not enough data
- Profit backed by cash (accruals)No
- DebtUnknown
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 32% more shares since 2021
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 9 March 2026
- Next quarterly (estimated, 10-Q)
- n/a
Who owns it
1 long-term investor we follow owns it, up from 0 last quarter. 74 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Polen CapitalDan Davidowitz | $3m | <0.1% | New |
Largest holders overall
- Gem Investment Advisors$18mAdded
- HighTower Advisors$11m
- Boothbay Fund Management$10mNew
- Aquamarine Financial (Cayman)$9m
- Pier Capital$9mNew
- UBS Group AG$8mAdded
- Apella Capital$5m
- ARK Investment Management$3mCut
- Polen Capital$3mNew
- Focus Partners Wealth$2mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
2 investors own more than 5%.
- Oramed Pharmaceuticals Inc.at least 20.0%(filed with 1 related holder)Since 24 April 2025
What they said
Share Purchase Agreement On April 24, 2025, Oramed Ltd. entered into a Share Purchase Agreement (the "Purchase Agreement") with the Issuer for the purchase by Oramed Ltd. of 14,110,121 Ordinary Shares of the Issuer, in a registered direct offering (the "Offering"), at a purchase…
Read the filing - Uzi SoferPassive investor15.8%Since 31 December 2022
| Holder | Stake | Since | |
|---|---|---|---|
Oramed Pharmaceuticals Inc. | at least 20.0% (filed with 1 related holder) | 24 April 2025 | What they saidShare Purchase Agreement On April 24, 2025, Oramed Ltd. entered into a Share Purchase Agreement (the "Purchase Agreement") with the Issuer for the purchase by Oramed Ltd. of 14,110,121 Ordinary Shares of the Issuer, in a registered direct offering (the "Offering"), at a purchase… Read the filing |
Uzi Sofer Passive investor | 15.8% | 31 December 2022 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 1 sold $2m, $1m of it under preset trading plans.
- Levy RaphiChief Financial OfficerSoldunder a preset trading plan
- Date
- 21 August 2026
- Shares
- 2,871
- Price
- $15.00
- Value
- $43,073
- Levy RaphiChief Financial OfficerSoldunder a preset trading plan
- Date
- 11 August 2026
- Shares
- 17,730
- Price
- $14.00
- Value
- $248,277
- Levy RaphiChief Financial OfficerSoldunder a preset trading plan
- Date
- 6 July 2026
- Shares
- 2,270
- Price
- $14.00
- Value
- $31,783
- Levy RaphiChief Financial OfficerSoldunder a preset trading plan
- Date
- 2 July 2026
- Shares
- 17,873
- Price
- $13.00
- Value
- $232,397
- Levy RaphiChief Financial OfficerSoldunder a preset trading plan
- Date
- 1 July 2026
- Shares
- 2,127
- Price
- $13.02
- Value
- $27,691
- Levy RaphiChief Financial OfficerSoldunder a preset trading plan
- Date
- 30 June 2026
- Shares
- 20,000
- Price
- $12.00
- Value
- $240,044
- Levy RaphiChief Financial OfficerSoldunder a preset trading plan
- Date
- 25 June 2026
- Shares
- 20,000
- Price
- $11.00
- Value
- $220,000
- Levy RaphiChief Financial OfficerSoldunder a preset trading plan
- Date
- 23 June 2026
- Shares
- 17,500
- Price
- $9.55
- Value
- $167,050
- Levy RaphiChief Financial OfficerSold
- Date
- 3 June 2026
- Shares
- 32,500
- Price
- $10.84
- Value
- $352,150
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 21 August 2026 | Levy Raphi Chief Financial Officer | Sold under a preset trading plan | 2,871 | $15.00 | $43,073 |
| 11 August 2026 | Levy Raphi Chief Financial Officer | Sold under a preset trading plan | 17,730 | $14.00 | $248,277 |
| 6 July 2026 | Levy Raphi Chief Financial Officer | Sold under a preset trading plan | 2,270 | $14.00 | $31,783 |
| 2 July 2026 | Levy Raphi Chief Financial Officer | Sold under a preset trading plan | 17,873 | $13.00 | $232,397 |
| 1 July 2026 | Levy Raphi Chief Financial Officer | Sold under a preset trading plan | 2,127 | $13.02 | $27,691 |
| 30 June 2026 | Levy Raphi Chief Financial Officer | Sold under a preset trading plan | 20,000 | $12.00 | $240,044 |
| 25 June 2026 | Levy Raphi Chief Financial Officer | Sold under a preset trading plan | 20,000 | $11.00 | $220,000 |
| 23 June 2026 | Levy Raphi Chief Financial Officer | Sold under a preset trading plan | 17,500 | $9.55 | $167,050 |
| 3 June 2026 | Levy Raphi Chief Financial Officer | Sold | 32,500 | $10.84 | $352,150 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
Alpha Tau Medical doesn’t file a US annual report (10-K), so we haven’t checked it.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.